Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tiburio Therapeutics

Request full access

Advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases

Cambridge, United StatesFounded 2018Biotech & Life Sciences

About Tiburio Therapeutics

Tiburio Therapeutics, Inc. is dedicated to developing transformative treatments for rare endocrine diseases, focusing on non-functioning pituitary adenomas (NFPAs) and other rare endocrine disorders. The company operates in the biopharmaceutical sector, targeting a niche market of patients with limited treatment options. Tiburio's clinical-stage pipeline includes two novel dopamine somatostatin chimeric compounds: TBR 760 and TBR 065. TBR 760 is designed to inhibit NFPA cell proliferation, potentially shrinking or halting tumor growth, and is expected to enter Phase 2 clinical trials. TBR 065 targets additional rare endocrine diseases. The business model revolves around advancing these compounds through clinical trials, securing regulatory approvals, and eventually commercializing the treatments. Revenue generation will primarily come from the sale of these specialized therapies to healthcare providers and institutions.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
53.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jan 2019 $31M $124M Lundbeckfonden Ventures · Longitude Capital · Alexandria Venture Investments · NEA ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Tiburio Therapeutics website traffic

Latest recorded traffic for Tiburio Therapeutics is 300 monthly website visits, up 36.4% over the last three months.

Latest monthly visits300 3-month web change+36.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Tiburio Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Tiburio Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Lundbeckfonden Ventures
  • Longitude Capital
  • Alexandria Venture Investments
  • NEA

Other known investors1 additional known investor

  • Lundbeckfonden
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tiburio Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tiburio Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.